{"id":390316,"date":"2019-12-06T00:00:00","date_gmt":"2019-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2019-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-06-12T11:36:26","modified_gmt":"2026-06-12T11:36:26","slug":"dlsfim0002-2019-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2019-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The axial spondyloarthritis (<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1) inhibitors (Amgen\u2019s Enbrel, AbbVie\u2019s Humira, Janssen\u2019s Remicade and Simponi \/ Simponi Aria, and UCB\u2019s Cimzia) and one\u00a0<abbr title=\"interleukin\">IL<\/abbr>-17 inhibitor (Novartis\u2019s Cosentyx). The\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are the most widely prescribed biologics in\u00a0<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>\u00a0patients refractory to nonsteroidal anti-inflammatory drugs (<abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s). However, these agents\u00a0face a competitive threat, both from the launch of cost-effective biosimilars and\u00a0the growing\u00a0<abbr title=\"interleukin\">IL<\/abbr>-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0in March 2019 for nonradiographic (nr)-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>, marking the first\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0approval for that subpopulation. The impending entry of additional\u00a0<abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors (Eli Lilly\u2019s Taltz, UCB\u2019s bimekizumab, and Kyowa Hakko Kirin\u2019s Lumicef) and the first oral targeted therapy for this indication (Pfizer\u2019s\u00a0<abbr title=\"Janus activated kinase\">Jak<\/abbr>\u00a0inhibitor Xeljanz) will also shift market dynamics.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large is the treatable\u00a0<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>\u00a0population, and how will diagnosis \/ drug-treatment rates change over time?<\/li>\n<li>What are interviewed experts\u2019 insights on current treatment options for ankylosing spondylitis (<abbr title=\"ankylosing spondylitis\">AS<\/abbr>) and nr-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>? What clinical needs remain unfulfilled?<\/li>\n<li>What pipeline products are the most promising, and what sales \/ uptake could they secure in\u00a0<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>? What therapies of note are progressing in earlier phases?<\/li>\n<li>What are the drivers and constraints in the\u00a0<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>\u00a0market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Geographies: United States,\u00a0<abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p>Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research<\/p>\n<p>Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands\/generics and epidemiological subpopulations<\/p>\n<p>Emerging therapies: Phase III\/<abbr title=\"preregistered\">PR<\/abbr>: 4\u00a0drugs; Phase II: 2\u00a0drugs<\/p>\n<p><strong>Product description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390316","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}